MLYS
Another lorundrostat check-in
Mineralys Therapeutics says it will present new data on lorundrostat at ASN Kidney Week 2026. Translation: the company is trying to keep its lead program in the conversation, and in biotech, that conversation is basically oxygen.
Why investors care
Lorundrostat is the whole point here. Any fresh presentation around a drug in development can matter because it may:
- reinforce the drug’s safety or efficacy story
- give investors a clearer read on the size of the opportunity
- nudge expectations ahead of bigger regulatory or trial milestones
The biotech treadmill
This is the part where biotech investing feels a little like waiting for the next season of your favorite show. Data drop, people squint at the slides, and suddenly everyone has a thesis. If the numbers look good, bulls start talking about upside. If not, the market gets moody in a hurry.
Big picture: this isn’t a revenue print or a deal announcement — it’s a pipeline update, which means the stock reaction will likely depend on whether the new data actually changes the story or just adds another chapter.